



COS-LEP Phase 4 Delphi Survey Round 1

Breakdown Analysis



Criteria for Consensus in to Round 2 by domain

- Any outcome rated 7–9 on Likert scale (critical outcome) by $\geq 70\%$ of any participant and 1–3 (limited importance) by no more than 15% of any single stakeholder group.
- Outcomes meeting this criteria advance to Round 2.
- N=62 outcome types met this criteria**

Criteria for No consensus by domain

- Any outcome type not meeting the Consensus In criteria will be defined as No consensus.
- These outcomes to be listed at the end of the Round 2 survey for further consideration.
- N=109 outcome types met this criteria**

Criteria for Consensus Out

- Any outcome with $\geq 70\%$ of all participants rated 1–3 (not important) for an outcome in any round.
- No outcomes in Round 1 met this criterion.**

COMET Core Area – Mortality

Summary of Core Area

- Outcome types advancing to Round 2
 - All-cause Mortality, Mortality attributable to Leptospirosis, Survival at a future defined time point
- Outcomes types with No Consensus
 - Time to death

Detailed analysis by outcome type

All-cause mortality

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Mortality attributable to Leptospirosis

Overall 83% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Time to death

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 15%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Survival at a future defined time point

Overall 77% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

COMET Core Area – Physiological/Clinical

Summary of Core Area

Outcome types advancing to Round 2

- **Blood and Lymphatic systems** – disseminated intravascular coagulation (DIC)
- **General outcomes** – haemodynamic shock, multi-organ failure
- **Hepatobiliary** – liver failure
- **Infection and Infestation** – prevention of confirmed case of leptospirosis, complication of leptospirosis (general), prevention of clinical manifestation of disease, prevention of clinical manifestation of disease confirmed by laboratory testing
- **Nervous system** – improving CNS manifestations, encephalopathy, seizure, CNS haemorrhagic manifestations
- **Pregnancy, puerperium, and perinatal** – fetal death, neonatal death, preterm birth, adverse infant/fetal outcomes (general), admission to neonatal intensive care
- **Renal and urinary** – renal failure, acute kidney injury, oliguria, change in urine output, biochemical measurements of renal function (general), development of chronic kidney disease (CKD), stage of CKD (various criteria), normalisation of renal function, major adverse kidney event (death, need for renal replacement, and persistent renal dysfunction)
- **Respiratory, thoracic, and mediastinal** – development of pulmonary haemorrhage, respiratory distress, severity of respiratory distress, respiratory failure, respiratory complications

Summary of Core Area (cont)

Outcomes types with No Consensus

- **Blood and Lymphatic systems** – presence of anaemia, Duration of anaemia, change in haemoglobin levels, revealed bleed, duration of bleed, leukocytosis, erythrocyte sedimentation rate (ESR) level, platelet counts, presence of thrombocytopenia, normalisation of haematological parameters (non-specific), improvement of platelet counts (non-specific), days until normalisation of platelets
- **Cardiac** – cardiac manifestations (non-specific), ECG abnormalities, cardiac arrhythmia, normalisation of cardio-respiratory function (non-specific)
- **Eye** – prevention of conjunctival suffusion, duration of conjunctival suffusion
- **Gastrointestinal** – pancreatitis (general), pancreatitis (by subtype), complications of pancreatitis, bedside index for severity in acute pancreatitis, duration of gastrointestinal symptoms (non-specific), gastrointestinal haemorrhage
- **General outcomes** – morbidity (non-specific), collapse, duration of vomiting, duration of myalgia, duration of general symptoms, development of any complications at set timepoint, change in clinical characteristics, change in functional signs, inadequate clinical response, time to resolution of organ dysfunction, resolution of symptoms (non-specific), time to resolution of symptoms (non-specific), resolution of symptoms at set time period
- **Hepatobiliary** – hepatic tenderness, clinical jaundice, hyperbilirubinaemia, change in bilirubin values, normalisation of liver function (non-specific), need for cholecystectomy
- **Immune system** – immune/inflammatory biochemical markers, improvement of parameters of oxidative stress and increase in antioxidant capacity, association of inflammatory marker with onset of Jarisch-Herxheimer reaction
- **Infection and Infestation** – days of fever, resolution of fever within specified time frame, persistent fever, prevention of the clinical diagnosis of leptospirosis, prevention of probable case of leptospirosis, baseline IgM remains zero, baseline IgM non-zero, presence of antibodies to leptospira species, fourfold rise in antibody titre, rising antibody titre, decreasing antibody titre, negative microscopic agglutination test, change in leptospira antibody levels over time, positive blood culture, positive urine culture, growth inhibition testing on serum, no evolution in infection, stable disease, manifestation of severe disease, attack rates, quantitative change in leptospiraemia, persistent immune response to subsequent infection, chronic post-leptospirosis symptoms
- **Musculoskeletal and connective tissue** – symptoms of arthritis
- **Nervous system** – meningitis syndrome, disease associated paralysis, duration of headache
- **Pregnancy, puerperium, and perinatal** – low birth weight, live birth, term birth, median neonatal birth weight, median gestational age at delivery
- **Renal and urinary** – intradialysis mean arterial pressure (mmHg), time to recovery of renal function, fluid balance, fluid intake (net/gross)
- **Respiratory, thoracic and mediastinal** – Partial pressure of arterial blood oxygen by the fraction of inspired oxygen (P/F) ratio, normalisation of cardio-respiratory functions, normalisation of radiographic imaging

Detailed analysis by outcome domain and type

Blood and Lymphatic systems

Anaemia

Overall 60% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of Anaemia

Overall 46% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Change in haemoglobin levels

Overall 51% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Revealed bleed

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of bleed

Overall 61% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%

- Patient/General Public group 0%

Leukocytosis

Overall 53% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

ESR

Overall 53% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 21%
- Other specialty clinician group 10%
- Global health researcher group 30%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Platelet count

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Thrombocytopenia

Overall 67% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Haematocrit level

Overall 46% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 0%
- Global health researcher group 10%

Cardiac

Anaemia

Overall 56% rated ≥ 7

- Allied Health Profession group 0%
- Patient/General Public group 0%

DIC

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalisation of haematological parameters (non-specific)

Overall 54% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%

Proportion rating ≤ 3 , by stakeholder group

- Patient/General Public group 0%

Improvement of platelet counts (non-specific)

Overall 52% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Days until normalisation of platelets

Overall 53% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- ID clinician group 6%

- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

ECG abnormality

Overall 58% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 10%
- Global health researcher group 10%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Cardiac arrhythmia

Overall 66% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 20%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalisation of cardio-respiratory functions (non-specific)

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 20%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Eye

Prevention of conjunctival suffusion

Overall 41% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 23%
- Other specialty clinician group 0%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of conjunctival suffusion

Overall 46% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 17%
- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Gastrointestinal

Pancreatitis (general)

Overall 58% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%

- Other specialty clinician group 0%
- Global health researcher group 5%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Pancreatitis (by sub-type)

Overall 52% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 20%
- Global health researcher group 25%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Complications of pancreatitis

Overall 51% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 15%
- Other specialty clinician group 10%
- Global health researcher group 20%

General outcomes

Morbidity (non-specific)

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 15%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Bedside for severity in acute pancreatitis

Overall 53% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of gastrointestinal symptoms (non-specific)

Overall 50% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- Allied Health Profession group 0%
- Patient/General Public group 0%

Haemodynamic shock

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%

- ID clinician group 10%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Gastrointestinal haemorrhage

Overall 70% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Multi-organ failure

Overall 80% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Collapse

Overall 53% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 20%
- Global health researcher group 10%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Duration of vomiting

Overall 43% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 20%
- Global health researcher group 20%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of myalgia

Overall 49% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 10%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of general symptoms

Overall 54% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Development of any complication at a set timepoint

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Change in clinical characteristics

Overall 56% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Change in functional signs

Overall 58% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 10%
- Global health researcher group 15%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Inadequate clinical response

Overall 61% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Time to resolution of organ dysfunction

Overall 68% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%

- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Resolution of symptoms (non-specific)

Overall 63% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Time to resolution of symptoms (non-specific)

Overall 64% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Resolution of symptoms at set time period)

Overall 60% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Hepatobiliary

Liver failure

Overall 82% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Hepatic tenderness

Overall 59% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 10%
- Global health researcher group 5%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Clinical jaundice

Overall 67% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Hyperbilirubinaemia

Overall 69% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 0%

- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Change in bilirubin levels

Overall 66% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalization of liver function (non-specific)

Overall 66% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for cholecystectomy

Overall 44% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 31%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Immune system

Immune/inflammatory biochemical markers

Overall 57% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Improvement of parameters of oxidative stress and increase antioxidant capacity

Overall 51% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 17%
- Other specialty clinician group 10%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Association of inflammatory marker with onset of Jarisch–Herxheimer reaction

Overall 59% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%

- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Musculoskeletal and connective tissue

Symptoms of arthritis

Overall 40% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 10%
- Global health researcher group 20%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Nervous system

Meningitis syndrome

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 20%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of headache

Overall 51% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Improving CNS

manifestations

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 10%

Disease associated paralysis

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%

Encephalopathy

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Seizure

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

CNS haemorrhagic manifestation

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Pregnancy, puerperium, and perinatal

Low birth weight

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Neonatal death

Overall 80% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Live birth

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Fetal death

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%

Preterm birth

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%

- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Term birth

Overall 66% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Adverse infant/fetal outcome (general)

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%

Renal and urinary

Intradialysis mean arterial pressure (mmHg)

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 10%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Admission to neonatal intensive care

Overall 70% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Median neonatal birth weight

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 20%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Median gestational age at delivery

Overall 59% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 20%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%

- Other specialty clinician group 20%
- Global health researcher group 10%

Renal failure

Overall 84% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Acute kidney injury

Overall 89% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Oliguria

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Change in urine output

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Biochemical measurements of renal function (general)

Overall 73% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Development of chronic kidney disease (CKD)

Overall 73% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Stage of CKD (various criteria)

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Time to recovery of renal function

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 10%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalisation of renal function

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Major Adverse Kidney Event

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Fluid balance

Overall 66% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%

- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Fluid intake (net/gross)

Overall 59% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Respiratory, thoracic and mediastinal

Development of pulmonary haemorrhage

Overall 83% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Respiratory distress

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Severity of respiratory distress

Overall 76% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Respiratory failure

Overall 80% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Partial pressure of arterial blood oxygen by the fraction of inspired oxygen (P/F) ratio

Overall 69% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Evolution of lung pathology

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 15%
- Other specialty clinician group 20%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Respiratory complications

Overall 76% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalisation of cardio-respiratory functions

Overall 64% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Normalisation of radiographic imaging

Overall 51% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 17%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 14%
- Patient/General Public group 0%

COMET Core Area – Life Impact

Summary of Core Area

Outcome types advancing to Round 2

- **Global quality of life** – quality of life (non-specific)
- **Delivery of care** – reduce outbreak events, health system responsiveness/readiness for outbreaks, accessibility to healthcare, adherence to assigned intervention

Outcomes types with No Consensus

- **Cognitive functioning** – knowledge/awareness of risk factors, behaviour related to risk factors
- **Blood and Lymphatic systems** – presence of anaemia, Duration of anaemia, change in haemoglobin levels, revealed bleed, duration of bleed, leukocytosis, erythrocyte sedimentation rate (ESR) level, platelet counts, presence of thrombocytopenia, normalisation of haematological parameters (non-specific), improvement of platelet counts (non-specific), days until normalisation of platelets
- **Delivery of care** – development of antimicrobial resistance
- **Personal circumstances** – days lost from work, duration until return to normal work

Detailed analysis by outcome domain and type

Cognitive functioning

Knowledge/awareness of risk factors

Overall 66% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Behaviour related to risk factors

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 20%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Global quality of life

Quality of life (non-specific)

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Delivery of care

Reduce outbreak events

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Accessibility to healthcare

Overall 82% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Adherence to assigned intervention

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Health system

responsiveness/readiness for outbreaks

Overall 81% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Adherence to assigned intervention

Overall 82% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Development of antimicrobial resistance

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Personal circumstances

Days lost from work

Overall 67% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%

- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Days lost from work

Overall 62% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

COMET Core Area – Resource Use

Summary of Core Area

Outcome types advancing to Round 2

- **Economic** – cost-effectiveness of treatment
- **Hospital** – days of clinical illness, need for hospitalisation, days of hospitalisation attributable to leptospirosis, intensive treatment unit admission, duration of intensive treatment unit admission, need for hospitalisation attributable to leptospirosis, complete medical discharge from hospital/clinic
- **Need for further intervention** – duration of antibiotic use, need for high-flow nasal oxygen, need for inotropic support, need for dialysis, renal replacement free survival, need for haemofiltration, major adverse kidney event, treatment failure, need for subsequent antimicrobials

Outcomes types with No Consensus

- **Economic** – economic outcomes
- **Need for further intervention** – need for mechanical ventilation, duration of mechanical ventilation, need for non-invasive ventilation, duration of extracorporeal membrane oxygenation, duration of inotropic support, number of dialysis sessions, duration of dialysis, ultrafiltration rate (ml/dialysis session), need for blood product transfusion, partial treatment response

Detailed analysis by outcome domain and type

Economic

Economic outcomes

Overall 62% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Cost-effectiveness of treatment

Overall 77% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Hospital

Days of clinical illness

Overall 78% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- | | |
|--------------------------------------|-------------------------------------|
| • ID clinician group 6% | • Global health researcher group 0% |
| • Other specialty clinician group 0% | |

- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for hospitalisation

Overall 84% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Days of hospitalisation

Overall 77% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Days of hospitalisation attributable to leptospirosis

Overall 80% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Intensive Treatment Unit admission

Overall 83% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of Intensive Treatment Unit admission

Overall 77% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for hospitalisation attributable to leptospirosis

Overall 79% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Complete medical discharge from hospital/clinic

Overall 86% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for further intervention

Duration of antibiotic case

Overall 74% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for mechanical ventilation

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 20%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of mechanical ventilation

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%

- Other specialty clinician group 10%
- Global health researcher group 20%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for non-invasive ventilation

Overall 68% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 20%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for high-flow nasal oxygen

Overall 72% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for extracorporeal membrane oxygenation

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of extracorporeal membrane oxygenation

Overall 64% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Need for inotropic support

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Duration of inotropic support

Overall 59% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for dialysis

Overall 82% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%

- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Renal replacement free survival

Overall 71% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Number of dialysis sessions

Overall 62% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Duration of dialysis

Overall 62% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Ultrafiltration rate (ml/dialysis session)

Overall 58% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 15%
- Other specialty clinician group 30%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for haemofiltration

Overall 79% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 10%
- Global health researcher group 0%

- Allied Health Profession group 0%
- Patient/General Public group 0%

Major adverse kidney event

Overall 92% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for blood product transfusion

Overall 63% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 10%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Treatment failure

Overall 83% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 10%
- Global health researcher group 0%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Partial treatment response

Overall 59% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Need for subsequent antimicrobial

Overall 64% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 0%
- Other specialty clinician group 0%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

COMET Core Area – Adverse events

Summary of Core Area

Outcome types advancing to Round 2

- **Adverse events/effects** – drug safety, serious adverse events, safety (general)

Outcomes types with No Consensus

- **Adverse events/effects** – manifestations of Jarisch-Herxheimer reaction, Jarisch-Herxheimer reaction manifestation association by antibiotic type, manifestation of nosocomial infection, non-serious adverse events, adverse events/side effects (non-specific)

Detailed analysis by outcome domain and type

Adverse events/effects

Manifestations of Jarisch-Herxheimer reaction

Overall 66% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Jarisch-Herxheimer reaction manifestation association by antibiotic type

Overall 60% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 13%

- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Manifestation of nosocomial infection

Overall 54% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 15%
- Other specialty clinician group 0%
- Global health researcher group 25%
- Allied Health Profession group 0%

- Patient/General Public group 0%

Drug safety

Overall 93% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 2%
- Other specialty clinician group 10%
- Global health researcher group 15%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Non-serious adverse events

Overall 40% rated ≥ 7

Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 10%

- Other specialty clinician group 30%
- Global health researcher group 10%
- Allied Health Profession group 14%
- Patient/General Public group 0%

Serious adverse events

Overall 83% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 8%
- Other specialty clinician group 10%

- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%

Safety (general)

Overall 73% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 4%
- Other specialty clinician group 0%
- Global health researcher group 10%
- Allied Health Profession group 0%

- Patient/General Public group 0%

Adverse events/side effects (non-specific)

Overall 60% rated ≥ 7
Proportion rating ≤ 3 , by stakeholder group

- ID clinician group 6%
- Other specialty clinician group 20%
- Global health researcher group 5%
- Allied Health Profession group 0%
- Patient/General Public group 0%